Anti-complementary agents from natural products

Chinese Journal of Natural Medicines

Volumn 5, Issue 5, 2007, Pages 322-332

  Xu, Han ^a   Zhang, Yun Yi ^a   Zhang, Jian Wen ^b   Chen, Dao Feng ^a  

^a FUDAN UNIVERSITY   (China)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Anti complimentary agent; Chemical structure; Clinical application; Natural product; Pharmacological activity

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANGELICA ACUTILOBA EXTRACT; ARTEMISIA PRINCEPS EXTRACT; CNIDIUM OFFICINALE EXTRACT; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT COMPONENT C9; CURCUMA LONGA EXTRACT; DIPSACUS ASPEROIDE EXTRACT; FUCOIDIN; GANODERMA LUCIDUM EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA URALENSIS EXTRACT; IMMUNOGLOBULIN; KAEMPFEROL DERIVATIVE; LITHOSPERMUM EUCHROMUM EXTRACT; NATURAL PRODUCT; PAEONIA LACTIFLORA EXTRACT; PLANT EXTRACT; PLANTAGO ASIATICA EXTRACT; POLYSACCHARIDE SULFATE; QUERCETIN DERIVATIVE; STIGMASTEROL; THYMUS VULGARIS EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIZIPHUS JUJUBA EXTRACT;

ACHYROCLINE; ACHYROCLINE SATUREIOIDES; ADULT RESPIRATORY DISTRESS SYNDROME; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ANGELICA; ANGELICA ACUTILOBA; ARTEMISIA; ARTEMISIA PRINCEPS; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CAPILLARY LEAK SYNDROME; CARDIOPULMONARY BYPASS; CNIDIUM; CNIDIUM OFFICINALE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; CURCUMA LONGA; DIPSACACEAE; DRUG STRUCTURE; GANODERMA LUCIDUM; GINSENG; GLOMERULONEPHRITIS; GLYCYRRHIZA URALENSIS; GRAFT REJECTION; HEART INFARCTION; HUMAN; JUJUBE; LITHOSPERMUM; LITHOSPERMUM EUCHROMUM; MULTIPLE ORGAN FAILURE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PAEONIA; PAEONIA LACTIFLORA; PATHOGENESIS; PLANTAGO; PLANTAGO ASIATICA; RHEUMATOID ARTHRITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THYME;

EID: 35348817970     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Makridea SC. Therapeutic inhibition of the complement system [J]. Pharmacol Rev, 1998, 50: 59-87.
2. Lustep HL, Clark WM. Current status of neuroprotective agents in the treatment of acute ischemic stroke [J]. Curr Neurol Neurosci Rep, 2001, 1(1):13-18.
3. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study[J]. The Lancet, 2003, 361: 1767-1772.
4. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis [J]. BMJ, 2003, 326: 1358-1362.
5. Zhou B, Liu J, Zhu J, Chin Pharma, 2002,11(6): 43-44.
6. Wang XL, Tang F, Li HM. J Chin Physician, 2002, 4(11): 1291-1293.
7. Morgan BP, Harris CL. Complement therapeutics; history and current progress[J]. Morlecular Immunology, 2003, 40: 159-170.
8. Wu ZH. Foreign Med Sci (Immonology), 2003, 26(3): 145-148.
9. Blondin C, Chaubet F, Nardella A, et al. Relationships between chemical characteristics and anticomplementary activity of fucans [J]. Biomaterials, 1996, 17(6): 597-603.
10. Catherine B, Elizabeth F, Catherine BV, et al. Inhibition of complement activation by natural sulfated polysaccharide (Fucans) from brown seaweed[J]. Mol Immunol, 1994, 31(4):247-253.
11. Doniel R, Berteau O, Chevolot L, et al. Regioselective desulfatation of sulfated L-fucopyranoside by a new sulfoesterase from the marine mollusk. Pecten maximus [J]. Eur J Biochem, 2001, 268: 5617-5626.
12. Chevolot L, Mulloy B, Ratiskol J, et al. A dissacharide repeat unit is the major structure in fucoidan from two species of brown algae [J]. Carbohydr Res, 2001, 330:529-535.
13. Tissot B, Montdargent B, Chevolot L, et al. Interaction of fucoidan with the proteins of the complement classical pathway[J]. Biochim Biophys Acta, 2003, 1651:5-16.
14. Tissot B, Daniel R, Place C. Interaction of the C1 complex of complement with sulfated polysaccharide and DNA probed by single molecule fluorescence microscopy [J]. Eur J Biochem, 2003, 270: 4714-4720.
15. Tissot B, Gonnet F, Iborra A, et al. Mass spectrometry analysis of the oligomeric C1q protein reveals the B chain as the target of trypsin cleavage and interaction with fucoidan[J]. Biochemistry, 2005, 44 (7):2602-2609.
16. Tomoda M, Ichikawa M, Plant mucilages XL. A representative mucilage, "Hibiscus-mucilage SF," from the flower buds of Hibiscus syriacus [J]. Chem Pharm Bull, 1987, 35(6): 2360-2365.
17. M Tomoda. R Gonda. M Adachi. Plant mucilages XXXIX. a representative mucilage, "Hibiscus-mucilage SL", from the leaves of Hibiscus syriacus [J]. Chem Pharm Bull, 1986, 34: 4133-4140.
18. Tomoda M, Shimizu N, Gonda R. Plant mucilages XXXVI. Isolation and characterization of a mucilage, "Okra-mucilage R", from the roots of Abelmoschus esadentus [J]. Chem Pharm Bull, 1985, 33: 3330-3336.
19. Tomoda M, Gonda R, Shimizu N, et al. Plant mucilages XLII. An and-complementary mucilage from the leaves of Mulva sylvestris var. mauritiana [J]. Chem Pharm Bull, 1989, 37(11): 3029-3032.
20. Noriko S, Masashi T, Liumi S, et al. Plant mucilages X III of Hibiscus rosa-sinensis [J]. Bid Pharm Bull, 1993, 16(8): 735-739.
21. Masashi T, Keiko M, Noriko S, et al. Characterization of two novel polysaccharides having immunological activities from the root of Panax ginseng [J]. Biol Pharm Bull, 1993, 16(11): 1087-1090.
22. Ryoko G, Masashi T, Naoko O, et al. Arabinogalactan core structure and immunological activities of ukonan C, an acidic polysaccharide from the rhizome of Curcuma longa [J]. Bid Pharm Bull,1993, 16 (3):235-238.
23. Masashi T, Keiko M, Noriko S, et al. Charachterization of a neutral and an acidic polysaccharide having immunological activities from the root of Paeonia lactiflora [J]. Biol Pharm Bull, 1993, 16 (2): 1207-1210.
24. Masashi T, Naoko O, Ryoko G, et al. An acidic polysaccharide having immunological activities from the rhizome of Cnidium officinale [J]. Chem Pharm Bull, 1992, 40(11):3025-3029.
25. Katsutoshi T, Masashi T, Noriko S. Core sructure of glyrrhizan GA, the main polysaccharide from the stolon of Giycyrrhiza glabra var. glandulifera; anti-complementary and alkaline phosphatase-inducing activities of the polysaccharide and its degradation products [J]. Chem Pharm Bull, 1992, 40(9):2487-2490.
26. Noriko S, Masashi T, Katsutoshi T, et al. The core structure and immunological activities of Glycyrrhizan UA, the main polysaccharide from the root of Glycyrrhiza uralensis [J]. Chem Pharm Bull, 1992, 40(8):2125-2128.
27. Yamada H, Ohtani K, Kiyohara H, et al. Purification and chemical properties of anti-complementary polysaccharide from the leaves of Artemisia princeps [J]. Planta Meal, 1985, 51(2): 21-125.
28. Haruki Y, Takayuki N, Jong CC, et al. Mode of complement activation by acidi heteroglycans from the leaves of Artemisia princeps PAM [J]. Chem Pharnm Bull, 1991, 39(8):2077-2081.
29. Yamada H, Kiyohara H, Cyong JC, et al. Structural characterisation of an anti-complementary arabinogalactan from the roots of Angelica acutiloba Kitagawa[J]. Carbohydr Res, 1987, 159(2): 275-291.
30. Kiyohara H, Cyong JC, Yamada H. Structure and anti-complementary activity of pectic polysaccharides isolated from the root of Angelica acutiloba Kitagawa [J]. Carbohydr Res, 1988, 182(2): 259-275.
31. Yamada H, Cyong JC, Olsuka Y. Purification and characterization of complement activating-acidic polysaccharide from the root of Lithospermum euchromum Royle [J]. Int J Immunopharmacol, 1986, 8(1): 71-82.
32. Yamada H, Nagai T, Cyong JC, et al. Relationship between chemical structure and anti-complementary activity of plant polysaccharides[J]. Carbohydr Res, 1985, 144: 101-111.
33. Puhlmam J, Kuaus U, Tubaro L, et al. Immunotogically active metallic ion-containing polysaccharides of Achyrocline satureioides [J]. Phytochemistry, 1992, 31(8):2611-2621.
34. Sendl A, Mulinacci N, Vincieri FF, et al. Anti-inflammatory and immunoligical active pilysaccharides of Sedum telephium [J]. Phytochemistry, 1993, 34(5): 1357-1362.
35. Fabian B, Maria C, Maria CM, et al. Neutral polysaccharide from Cedrela tubiflora with anticomplementary activity[J]. Phytochemsitry, 1999, 50:57-62.
36. Zhao QC, Kiyohara H, Yamada H, et al. Anti-complementary neutral polysaccharides from leaves of Artemisia princeps [J]. Phytochemistry, 1994, 35: 73-77.
37. Gao QP, Hiroaki K, Jong CC, et al. Chemical properties and anti-complementary activities of heteroglycans from the leaves of Panax ginseng [J]. Planta med, 1991, 57:132-136.
38. Yamada H, Ra KS, Kiyohara H, et al. Characterization of anticomplementary neutral polysaccharides from the roots of Bupleurum falcatum [J]. Phytochemistry, 1988, 27:3163-3168.
39. Yong WZ, Hiroaki K, Tsukasa M, et al. Fractionation and chemical properties of immunomodulating polysaccharides from roots of Dipsacus asperoide [J]. Planta Med, 1997, 63:393-399.
40. Hyug C, Dong HS, Bum SH, et al. Purification and biological activity of acidic polyaccharide from leaves of Thymus vulgaris L[J]. Biol Pharm Bull, 2001, 24(8): 941-946.
41. Hyug C, Won JJ, Dong HS, et al. Purification and characterization of anti-complementary polysaccharide from leaves of Thymus vulgaris L [J]. Chem Pharm Bull, 2001, 49(6):762-764.
42. Zhang Q, Lei LS, Lin QB. Pharma & Clin Chin Mat Med, 1998, 14(5): 19-21.
43. Olafsdottir ES, Inglfsdottir K, Barsett H, et al. Immunological active (13)-(14)-α-D-glucan from Cetraria islandica [J]. Phytomedicine, 1999, 6(1):33-39.
44. Puhlmann J, Zenk MH, Wagner H. Immunologically active polysaccharides of arnica Montana cell cultures[J]. Phytochemistry, 1991, 30(4): 1141-1145.
45. Kanyanga C, Tess DB, Aleidis L, et al. In vitro anticomplementary activity of constituents from Morinda morindoides [J]. J Nat Prod, 1995, 58(3):372-378.
46. Kean YJ, Sei RO, Park SH, et al. Anticomplement activity of tiliroside from the flower buds of Magnolia fargesii [J]. Biol Pharm Bull, 1998, 21(10): 1077-1078.
47. Park SH, Sei RO, Keun YJ, et al. Acylayed flavonol glycosides with anticomplementary activity from Persicaria lapathifolia [J]. Chem Pharm Bull, 1999, 47(10): 1484-1486.
48. Min BS, Lee SY, Kim JH, et al. Anticomplement activity of constituents from the stem-bark of Juglans mandsharica [J]. Bil Pharm Bull, 2003, 26(7): 1042-1044.
49. Sei RO, Dong S K, Lm SL, et al. Anticomplementary activity of constituents from the keartwood of Caeslapinia sappan [J]. Planta Med, 1998, 64: 456-458.
50. Haroki Y, Tsukasa M, et al. Effects of phytosterols on anticomplementary activity[J]. Chem Pharm Bull, 1987, 35(12):4851-4855.
51. Fatima C, Rawiwan W, Pichai S, et al. Clionasterol:a potent inhibitor of complement component C1 [J]. Planta Med, 2003, 69: 171-174.
52. Deyama T, Nishibes S, Nakazama Y. Constituents and pharmacological effects of Eucommia and Siberian ginsery [J]. Acta Pharmacol Sin, 2001, 22(2): 1057-1070.
53. Kanyanga C, Nina H, Sanda A, et al. Complement-inhibiting iyidoids from Morinda morindoidss [J]. J Nat Prod, 2003, 66:97-102.
54. Byung SM, Jiang JG, Masao H, et al. Anticomplement activity of terpenoids from the spores of Ganoderma lucidum [J]. Planta Med, 2001, 67:811-814.
55. Geetha T, Varalakshmi P. Anticomplement activity of triterpenes of Crataeva murvala stem bark in adjuvant arthritis in rats[J]. General Pharmacology, 1999, 32:495-497.
56. Hideaki M, Norimichi T, Masayuki Y, et al. Studies on Alismatis Rhizoma II. Anti-complementary activities of methanol extract and terpene components from Alismatis Rhizoma (dried rhizome of Alisma orientale) [J]. Biol Pharm Bull, 1998, 21(12):1317-1321.
57. Lee SM, Kim JH, Zhang Y, et al. Anticomplementary acitivity of protostame-type triterpenes from Alismatis rhizoma [J]. Arch Pharm Res, 2003, 26(6): 463-465.
58. Oh SR, Jung SK, Son KH, et al. In vitro anticomplementary activity of Hederagen in saponins isolated from roots of Dipascus asper [J]. Arch Pharm Res, 1999, 22(3):317-319.
59. Vogt W. Factors in cobra venoms affecting the complement system [J]. Toxicon, 1982, 20 (1): 299-303.
60. Vogel CW, Smith CA, Muller- Eberhard HJ. Cobra venom factor: structural homology with the third component of human complement [J]. J Immunol, 1984, 133(6): 3235-3241.
61. Smith CA, Vogel CW, Muller-Eberhard HJ. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement [J]. J Biol Chem, 1982, 257(17): 9879-9882.
62. Vogel C, Muller-Eberhard HJ. Cobra venom factor: improved method for purification and biochemical characterization [J]. J Immnnol Methods, 1984, 73:203-220.
63. Liang ZP, Mai JX, Huang SJ. Chin J Pathophy 1994:654-658.
64. Pang AS, Minta JQ. Inhibition of vitamin D2-induced arteriosclerosis in rats by depletion of complement with cobra venom factor [J]. Artery, 1980, 7 (2): 109-122.
65. Koyamada N, Miyatake T, Candlnas D, et al. Transient complement inhibition plus T-cell immamosuppression induces long-term survival of mouse-to-rat cardiac xenografts [J]. Tramp lantation, 1998, 65(9): 1210-1215.
66. Kobayashi T, Taniguchi S, Neeth ling FA, et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy [J]. Transplantation, 1997, 64(9): 1255-1261.
67. Kanyanga C, tess DB, Aleidis L, et al. In vitro biological activities of alkaloids from Cryptolepis sangninolenta [J]. Planta Med, 1996, 62:22-27.
68. kostalove D, Bukovsky M, Koscova H, et al. Anticomplement activity of Mahonia aq 1 uifolium bisbenzylissoquinoline alkaloids and berberine extract[J]. Ceska Slow Farm, 2001, 50(6):286-289.
69. Byung S M, Sun YL, Tung HK, et al. Lactones from the loves of Litsea japonica and their anticomplement activity[J]. J Nat Prod, 2003, 66: 1388-1390.
70. Bo YP, Byung S M, Sci RO, et al. Isolation and anticomplement activity of compounds from Dendropanax morbifera [J]. J Ethnopharmacol, 2004: 1-5.
71. Ling M, Diddlesden SJ, Morgan BP, et al. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement[J]. Clin Exp Immunol, 1995, 102: 582-588.
72. Yang K, Liu WY, Bai Y, J Fourth Mil Med Univ, 2000, 21(12): 1558-1560.
73. Abdelaaty AS, Faiza H, Shams II, et al. Anticomplementary activity of Cratagus sinaica [J]. Planta Med, 1996, 62:10-13.
74. Arriaga SM, Mottino AD, Almara AM. Inhibitory effect of bilirubin on complement-mediated hemolysis[J]. Biochim Biophys Acta, 1999, 1473(2-3): 329-336.
75. MCW Chan, CY Cheung, WH Chui, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells [ J]. Respir Res, 2005, 6: 135.
76. Yazdanbakhsh K, Scaradavou A. CR1-based inhibitors for prevention of complement-mediated immune hemolysis [J]. Drug News Perspect, 2004, 17(5): 314-320.
77. Zimmerman JL, Dellinger RP, Straube RC, et al. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome [J]. Crit Care Med, 2000, 28: 3149-3154.
78. Li JS, Sanders SP, Perry AE, et al. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmanary bypass[J]. Am Heart J, 2004, 147(1): 173-180.
79. Allegretti M, Moriconi A, Beccari AR, et al. Targeting C5a: recent advances in drug discovery [J]. Curr Med Chem, 2005, 12 (2): 217-236.
80. Wang Y, Rollins SA, Madri JA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease[J]. Proc Natl Aca Sci USA, 1995, 92:8955-8959.
81. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial [J ]. Circulation, 2003, 108(10): 1184, 1190.
82. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the complement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial [J]. Circulation, 2003, 108(10):1176-1183.
83. Verrier ED, Shernan SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial[J]. JAMA, 2004, 291(19):2319-2327.
84. Shernan SK, Fitch JC, Nussmeier NA, et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmanary bypass [J]. Ann Thorac Surg, 2004, 77 (3): 942-950.
85. Smith RA. Targeting anticomplement agents [J]. Biochem Soc Trans, 2002, 30(6): 1037-1041.
86. Buddhadeb M, Madan K, Lynn A, et al. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids[J]. J Med Chem, 2005, 48:274-286.
87. Liang AJ, Lin Y, Liu HZ. Pharm J Chin PIA, 2003, 19(5): 367-369.